Karo Pharma completes the acquisition of Sylphar International NV
Karo Pharma Aktiebolag (“Karo”) today announces that the previously announced acquisition of the Belgian fast-growing digital-first brand company Sylphar International NV (“Sylphar”) for EUR 290m has been successfully completed according to plan.
The transaction is expected to contribute positively to Karo’s market position and further enhance Karo’s strong platform for continued growth, particularly in the digital marketplace.
Effective today, Robin List, CEO of Sylphar, shall join the Karo Corporate Management Team, reporting to Christoffer Lorenzen, CEO. Robin shall continue to manage the Sylphar businesses and will be instrumental in the integration and forward operations of the combined companies.
For further information, please contact:
Christoffer Lorenzen, CEO, +46 735 017 620, christoffer.lorenzen@karopharma.com
Carl Lindgren, VP Business Development, +46 760 026 022, carl.lindgren@karopharma.com
This information is such that Karo Pharma Aktiebolag (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons indicated above, on 13 January at 15:30 CET.
About Karo Pharma
Karo Pharma delivers smart choices for everyday healthcare. We own and commercialize branded, original over-the-counter products and prescription medicines. Our products are available in more than 60 countries, with Europe and the Nordic region as our core markets. Karo Pharma is headquartered in Stockholm, Sweden and listed on Nasdaq Stockholm.
Forward-looking statements
This news release contains certain forward-looking statements that are based on uncertainty, as they relate to events and depend on circumstances that will occur in the future and which, by their nature, may have an impact on results of operations and the financial condition of Karo Pharma. Such forward-looking statements reflect our current expectations and are based on the information currently available. Karo Pharma cannot give any assurance as to whether such forward-looking statements will prove to be correct. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Tags: